{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:57:24Z","timestamp":1790621844468,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      <\/jats:styled-content>\n                      and could be a new treatment option for patients with AD. The aim of this first\u2010in\u2010human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the pharmacodynamic effects in patients with mild to moderate AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method and Materials<\/jats:title>\n                    <jats:p>This study consisted of Part A and Part B. In Part A, subjects were randomized and received XZ.700 10\u00a0\u03bcg\/g, XZ.700 30\u2009\u03bcg\/g, XZ.700 100\u2009\u03bcg\/g or vehicle twice daily for 7\u00a0days on nonlesional skin and on all lesions (1%\u2009\u2264\u2009BSA\u2009\u2264\u200910%). In Part B, subjects received XZ.700 100\u2009\u03bcg\/g or vehicle on all lesions twice daily for 14\u2009days (1%\u2009\u2264\u2009BSA\u2009\u2264\u200915%). Clinical scores and patient\u2010reported outcomes were recorded. Pharmacodynamic measurements were taken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 35 patients completed the study. Tolerability of XZ.700 was acceptable. XZ.700 100\u2009\u03bcg\/g showed no evidence of effect on cultured\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>S. aureus<\/jats:italic>\n                      <\/jats:styled-content>\n                      (estimated difference \u221252.9% CFU\/mL; 95% CI \u221288.4% to 90.8%), oSCORAD (1.03; 95% CI \u22125.20 to 7.26) or EASI (\u22120.534; 95% CI \u22122.48 to 1.41). Furthermore, XZ.700 treatment did not result in a significant reduction in the relative abundance of\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>S. aureus<\/jats:italic>\n                      <\/jats:styled-content>\n                      via metagenomics or other pharmacodynamic outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Tolerability and safety of short\u2010term topical administration of XZ.700 100\u2009\u03bcg\/g for 14\u2009days were acceptable in most participants; however, some local application\u2010site events occurred, and one hypersensitivity reaction led to discontinuation. XZ.700 did not demonstrate target engagement or clinical benefit\n                      <jats:italic>vs<\/jats:italic>\n                      . vehicle under the tested conditions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70630","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:45:51Z","timestamp":1781160351000},"page":"3448-3459","source":"Crossref","is-referenced-by-count":0,"title":["<scp>\n                      <i>S. aureus<\/i>\n                    <\/scp>\n                    colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double\u2010blind randomized clinical trial in patients with mild to moderate atopic dermatitis"],"prefix":"10.1002","volume":"92","author":[{"given":"Laura W. J.","family":"van der Meulen","sequence":"first","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"},{"name":"Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menthe E.","family":"Bergmans","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"},{"name":"Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Assil","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Klarenbeek","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke L.","family":"de Kam","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa J.","family":"Tibboel","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Brach","sequence":"additional","affiliation":[{"name":"Clinical Microbiomics A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn L.","family":"Herpers","sequence":"additional","affiliation":[{"name":"Regional Public Health Laboratory Kennemerland  Haarlem the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Frieling","sequence":"additional","affiliation":[{"name":"Micreos Human Health  Bilthoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"de Jong","sequence":"additional","affiliation":[{"name":"Micreos Human Health  Bilthoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benthe","family":"Freyee","sequence":"additional","affiliation":[{"name":"Micreos Human Health  Bilthoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B. A.","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"},{"name":"Department of Dermatology Erasmus Medical Centre  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-9090","authenticated-orcid":false,"given":"Robert","family":"Rissmann","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"},{"name":"Leiden Academic Centre for Drug Research Leiden University  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Niemeyer\u2013van der Kolk","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden the Netherlands"},{"name":"Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010018\u20100001\u2010z"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122767"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010021\u201000266\u20106"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31286\u20101"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2017.11.008"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.011"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14566"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00104\u201012"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah4680"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.03.014.Dysbiosis"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.132"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12792"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.790"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.018"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02273\u201021"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/08927014.2021.1887151"},{"key":"e_1_2_10_18_1","unstructured":"Emollient Guidance and Formulary Rationale for prescribing emollients[Internet].2023[cited 2026 Mar 22]. Available from:https:\/\/primarycare.northeastlondon.icb.nhs.uk\/wp-content\/uploads\/2023\/08\/Emollient_Formulary.pdf"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70608"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70229\/full"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1526096"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113929"},{"key":"e_1_2_10_23_1","first-page":"1","author":"Murray E","year":"2021","journal-title":"Clinical Setting"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.133"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600\u20100625.2000.009003165.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.39.1.175"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioflm.2024.100222"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70630","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70630","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:56:04Z","timestamp":1790618164000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/bcp.70630"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70630","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}